Subscribe to our news
Notice of stabilization measures in ChromoGenics during the period 23 – 31 March 2017 on Nasdaq First North, Stockholm
NOT FOR DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, TO NEW DISTRIBUTORS IN THE UNITED STATES OR FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE ILLEGAL BY APPLICABLE LAW
ChromoGenics AB (publ) announces that stabilizing trading have been carried out by Erik Penser AB (“EPB”) in ChromoGenics’ shares on Nasdaq First North, Stockholm.
As announced in connection with the offer for subscription of new shares in ChromoGenics and listing of company’s shares on Nasdaq First North, Stockholm (the “Offer”), EPB has the option, as stabilization firm, to perform trading in order to support the market price of the shares at a higher level than would otherwise have been prevailing in the market.
Stabilization transactions may be carried on Nasdaq First North, Stockholm, the OTC market or otherwise, at any time during the period beginning on the first day of trading of the shares on the Nasdaq First North, Stockholm, and end no later than 30 calendar days thereafter. EPB has no obligation to perform any stabilization and there is no guarantee that stabilization will be undertaken. If stabilization is started, it can also be terminated at any time without notice. Under no circumstances will the transaction be carried out in order to support the market price of the shares at the price higher than the price in the Offer.
EPB, acting as stabilization firm, has announced that stabilization trading has been carried out, in accordance with Article 5 (4) of the European Market Abuse Regulation 596/2014, on Nasdaq First North Stockholm as per below. Contact at EPB is Anders Kappling, tel: +46 8 463 80 00
|Issuer:||ChromoGenics AB (publ)|
|Instrument:||Stocks (ISIN SE0009496268)|
|Outcome of the Offer:||13,921,312 shares, of which stabilization max 121 312 shares|
|Offer Price:||8.50 SEK per share|
|Stabilization firm:||Erik Penser Bank AB (publ)|
|Date||Quantity||Price (highest)||Price (lowest)||Price (average)||Currency||Market place|
|2017-03-23||85 500||8,20||6,30||6,71||SEK||Nasdaq First North|
|2017-03-24||2 000||6,20||6,20||6,20||SEK||Nasdaq First North|
|2017-03-27||12 000||6,80||6,30||6,60||SEK||Nasdaq First North|
|2017-03-28||5 000||6,50||6,35||6,44||SEK||Nasdaq First North|
|2017-03-29||812||6,55||6,40||6,46||SEK||Nasdaq First North|
G&W Fondkommission is the financial advisor to ChromoGenics in connection with the transaction and appointed as Certified Adviser.
Thomas Almesjö, CEO
Susanne Andersson, CFO & Head of Communications
Tel: +46 18 430 0430
This information is such that ChromoGenics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and according to the Act (1991:980) regarding trading with financial instruments. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on April 3, 2017.
Every care has been taken in the translation of this interim report. In the event of discrepancies, the Swedish original will supersede the English translation.
ChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company’s unique electrochromic technology ConverLight™, provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started commercial sales to real estate projects in Scandinavia.
ChromoGenics is located in Uppsala and has about 20 employees. The technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser.
Publication and distribution of this announcement may in certain jurisdictions be restricted by law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and observe such restrictions. The information in this press release is not an offer to purchase, subscribe for or otherwise trade in shares or other securities in ChromoGenics.
This press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or other country where such action would require additional measures in addition to those following Swedish law or where this would contravene the laws or regulations of that country. The information in this press release may not be forwarded, reproduced or disclosed in ways that conflict with such restrictions. Failure to comply with this instruction may result in violation of the United States Securities Act of 1933 (the “Securities Act”) as amended, or applicable laws in other jurisdictions.